Posted by Michael Wonder on 05 Jan 2016
Gilead announces U.S. FDA priority review designation for sofosbuvir/velpatasvir for treatment of all genotypes of chronic hepatitis C infection
4 January 2016 - Gilead filed the NDA for SOF/VEL on October 28, 2015, and FDA has set a target action date under the Prescription Drug User Fee Act of June 28, 2016.
For more details, go to: http://www.gilead.com/news/press-releases/2016/1/gilead-announces-us-fda-priority-review-designation-for-sofosbuvirvelpatasvir-for-treatment-of-all-genotypes-of-chronic-hepatitis-c-infection
